About Us

With state-of-the-art technology platforms of next-generation sequencing, microarray, and mass spectrometry, CD Genomics provides reliable services to pharmaceutical and biotechnology companies as well as academia and government agencies, and enjoys a high reputation. We are proud of satisfying the needs of our clients both at home and abroad, which across more than 50 countries and districts. We always devote ourselves to providing you with the best and professional service.

CD Genomics – RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The CD Genomics scientists are ready to help you detect various types of RNA via meticulous and integrative approaches. CD Genomics has already updated the technology platform to mainstream NGS, microarray, and LC-MS/MS instruments. At present, our senior bioinformaticians have ever viewed more than ten thousand trace files and accumulated abundant experience with our Illumina HiSeq, Agilent microarray, QTRAP LC-MS/MS Systems. Help you to study (meta)transcriptomics, understand previously undetected changes happening in disease states and responses to therapeutics, changes under different environmental conditions, and more.

OUR VISION

To be the most trusted partner with pharmaceutical and biotechnology companies as well as academia and government agencies for RNA Sequencing, as well as integrated solutions that allow customers to comprehensively study coding and non-coding RNA of interest.

OUR MISSION

Submit high quality, high accuracy report on RNA and pathway analysis. To be the most trusted partner with pharmaceutical and biotechnology companies as well as academia and government agencies for RNA Sequencing and downstream bioinformatics analysis.

Dedicated Teams

Flexibility for EFFECTIVE and Efficient Execution

Experienced

Seamless Integration from Samples to Reports

ONE-STOP Service

State-of-the-art Facilities

logo
Copyright © CD Genomics. All rights reserved.